Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7332 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3186 | 0.4076 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4024 | 0.4348 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7956 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.1315 | 0.5 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3599 | 0.2673 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0851 | 0.0739 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.1315 | 0.1421 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0518 | 0.0559 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1315 | 0.5 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0851 | 0.0739 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4357 | 0.4709 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0518 | 0.0242 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.1315 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3186 | 0.4076 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7332 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9254 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1315 | 0.5 |
Brugia malayi | hypothetical protein | 0.003 | 0.1315 | 0.0059 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.1315 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3611 | 0.3902 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0851 | 0.0679 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0532 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.4147 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 95.2834 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.